key: cord-0830201-y5ddl6vm
authors: Kojima, N.; Qato, D. M.; Klausner, J. D.
title: Association of Increased Fluvoxamine Use with Reports of Benefit for COVID
date: 2022-01-27
journal: nan
DOI: 10.1101/2022.01.19.22269020
sha: 9deced91c48dbfc44a3fac32b277847f5389993c
doc_id: 830201
cord_uid: y5ddl6vm

Introduction: Several recent studies have found that fluvoxamine decreases the risk of serious disease progression among people with early COVID-19. In this study, we examined changes in the total number of fluvoxamine tablets dispensed across retail pharmacies in the U.S. Methods: We hypothesized that fluvoxamine prescriptions would increase substantially since March 2021 as an option for the early treatment of COVID-19. We used the IQVIA National Prescription Audit (NPA) Weekly nationally projected data for prescriptions dispensed from retail pharmacies for fluvoxamine from 27 December 2019 to 31 December 2021. We performed an interrupted-time series analyses on frequency of dispensing fluvoxamine tablets. Results: The weekly rate of dispensed tablets of fluvoxamine increased throughout the study period. The weekly number of dispensed tablets of fluvoxamine increased (11.1%) from a baseline of 1,586,154 (95% confidence interval [CI]: 1,563,960 to 1,608,348) to 1,762,381 (95% CI: 1,735,682 to 1,789,080) by December 2021. Conclusion: Our findings are consistent with a modest increase in the use of fluvoxamine for the treatment of COVID-19 associated with the discovery and media dissemination of the potential clinical benefit of fluvoxamine use.

23 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Introduction: Several recent studies have found that fluvoxamine decreases the risk of 25 serious disease progression among people with early SARS-CoV-2 infection. In this 26 study, we examined changes in the total number of fluvoxamine tablets dispensed 27 across retail pharmacies in the U.S. 28

Methods: We hypothesized that fluvoxamine prescriptions would increase substantially 29 since March 2021 as an option for the early treatment of SARS-CoV-2 infection. We CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.19.22269020 doi: medRxiv preprint

Several recent studies have found that fluvoxamine decreases the risk of serious 44 disease progression among people with early SARS-CoV-2 infection. 1-3 In March 2021 a 45 widely watched news program aired a report describing the potential benefit of 46 fluvoxamine for While several medications were developed to treat COVID-47 19, repurposing existing medications like fluvoxamine offer benefits, including 48 widespread availability, known safely profiles, and low cost, that newly approved 49 medications lack. 5 In this study, we examined changes in the total number of . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. (Figure) . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 27, 2022. 

Fluvoxamine vs Placebo and Clinical 98 Deterioration in Outpatients With Symptomatic

Clinical Trial

Prospective Cohort of Fluvoxamine for Early Treatment 101 of Coronavirus Disease 19

Effect of early treatment 104 with fluvoxamine on risk of emergency care and hospitalisation among patients 105 with COVID-19: the TOGETHER randomised, platform clinical trial

Finding a possible early treatment for COVID-19 in a 40-year-old 108 antidepressant. 60 Minutes. CBS

Fluvoxamine 112 for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence